Harbour Biomed

China
Shaxi, Fujian, China, 200032

Company profile

Harbour Biomed company profile

Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.

Business identity

Contact email
[email protected]
Phone number
+86-21-51370990
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$10M-$100M
Founded
2016-01-01, Year

Headquarters

Postal code
200032
Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
6
Total equity funding
$417.8M
Last funding
Post IPO Equity / $105M / 2025-03-21
Last equity funding
Post IPO Equity / $105M
Investors
20
Lead investors
6
Founders
4
Articles
171
Exited on
2020-12-10

Founders and investors

Founders

Frank GrosveldJeff HeJingsong WangLiang Schweizer

Lead investors

Advantech CapitalAstraZenecaGICHudson Bay Capital ManagementLegend CapitalSWFI

Investors

AstraZenecaCDH InvestmentsLegend CapitalOrbiMedVertex Ventures